Patents by Inventor Cristoforo Silvestri

Cristoforo Silvestri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
    Patent number: 10039724
    Abstract: The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 7, 2018
    Assignee: GW Research Limited
    Inventors: Colin Stott, Marnie Duncan, Vincenzo Di Marzo, Cristoforo Silvestri, Andrea Martella
  • 7-HYDROXY CANNABIDIOL (7-OH-CBD) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Publication number: 20170128385
    Abstract: The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.
    Type: Application
    Filed: June 29, 2015
    Publication date: May 11, 2017
    Inventors: Colin Stott, Marnie Duncan, Vincenzo Di Marzo, Cristoforo Silvestri, Andrea Martella